Sorin Group S.p.A. Acquires Gish Biomedical

MILAN--(BUSINESS WIRE)--Sorin Group, (Reuters Code: SORN.MI)(MIL:SRN), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has acquired Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies.

Based in California, Gish Biomedical designs and manufactures disposable medical devices for cardiovascular surgery, with a focus on the Perfusionist. Gish products have been marketed both in the United States and worldwide for over 25 years.

“We are excited by this opportunity to further strengthen our world leadership in providing patients and customers with the best solutions for extracorporeal circulation” said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.

The guidance previously provided to the market remains unchanged as a result of this transaction.

About Sorin Group

Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,600 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please visit: www.sorin.com

Contact:

Sorin Group Director, Corporate Communications Martine Konorski, +33 (0)1 46 01 33 78 Mobile: +33 (0)6 76 12 67 73 martine.konorski@sorin.com or Investor Relations Carla Vidra, +39 02 69969716 carla.vidra@sorin.com